From the patient perspective: The economic value of seasonal and H1N1 influenza vaccination

Abstract

Although studies have suggested that a patient’s perceived cost-benefit of a medical intervention could affect his or her utilization of the intervention, the economic value of influenza vaccine from the patient’s perspective remains unclear. Therefore, we developed a stochastic decision analytic computer model representing an adult’s decision of whether to get vaccinated. Different scenarios explored the impact of the patient being insured versus uninsured, influenza attack rate, vaccine administration costs and vaccination time costs. Results indicated that cost of avoiding influenza was fairly low, with one driver being required vaccination time. To encourage vaccination, decision makers may want to focus on ways to reduce this time, such as vaccinating at work, churches, or other normally frequented locations.

The potential economic value of a human norovirus vaccine for the United States

“…Although we have identified a range of potential costs per case averted depending on vaccine characteristics and age group vaccinated [−$303 ($25 vaccine in under 5 year olds) to $3,191 ($75 vaccine in 15 to 44 year olds)], it is not clear what costs would be considered acceptable as we have not conducted a formal analysis to determine a ‘break-even’ point or other threshold for vaccine cost. The cost per case averted for other vaccines varies widely; rotavirus vaccines are $138 (RotaTeq [27]) and $94 (Rotarix [28]), a $50 influenza vaccine ranges from $1,653 to $3,315 [29], and a $50 Lyme disease vaccine would cost $4,466 per case averted [30]. At $138 per case averted, routine rotavirus immunization was estimated, prior to introduction, to cost a total $216 million to society [27].…”

The cost of an Ebola case

“…the 2009 H1N1 pandemic), we had estimates for the cost of an influenza case. [2][3][4][5][6] A review of the literature reveals no other studies determining the costs associated with an Ebola case. While the report evaluated the overall (macroeconomic) impact of EVD, 7 the current study is the only one known to date to estimate direct medical and productivity losses on a per-case basis.…”

“…For example, our previous influenza work during the H1N1 pandemic has provided information that is useful to decision makers since the pandemic. [14][15][16][17][18][19][20][21] Thirdly, during the Ebola outbreak, other diseases do not cease their activity. Therefore, one may want to compare the impact of Ebola versus other currently active diseases to help make choices, even after the current outbreak subsides.…”

Costs of Adult Vaccination in Medical Settings and Pharmacies: An Observational Study

“…17 The most frequently reported barriers to such collaboration were concerns about record transfer and the required time and effort. 17 From the patient's perspective, the amount of time required for vaccination is a barrier, 18 and offering vaccination at a convenient location such as the workplace or a community pharmacy might encourage patient participation.…”